Intelligent OMICS

Intelligent OMICS Ltd ("Intellomx") discovers the biological targets that drive disease. We offer our services to pharma and apply our technology in-house too: Our own KRAS lung cancer assets are ready for out-licensing now. Intellomx offers a wide set of services to our clients and collaboration partners. Intellomx technology identifies the key drivers in disease pathways, revealing the underlying systems biology of multiple diseases. Intellomx technology uses proprietary artificial neural network algorithms to model non-linear biology, finding patterns that could not previously have been identified. Intellomx technology optimises diagnostic panels and creates companion diagnostics with the minimum number of biomarkers - ideal for lateral flow devices, PCR or similar platforms. Our Digital Twin provides a platform for rapid testing of off-target effects via disease pathways, saving costs and unnecessary animal trials. There is a revolution underway in drug discovery.".